TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Decrease of plasma glutamine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in S aureus nasal carriage
Endpoint domain: Adverse events/effects
Primary endpoint: Total medical cost during the first cycle of chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: global pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ADHD symptoms by greater or equal to 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in driving errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in self-reported critical traffic situations
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in mean concentration of IgE‐blocking factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in specific IgE concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in specific IgG(4) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in virtual reality skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum inspiratory muscle power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum rate of pressure development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diplopia (DVD) measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hormonal response (growth hormone)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Active plasma renin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Interobserver agreement on presence of tongue base collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver agreement on presence of epiglottis collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver agreement on presence of oropharynx collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diastolic aortic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic aortic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic distal coronary pressure (Pd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shoulder Rating Questionnaire (SRQ) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: shoulder satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response on CGI-I
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AbdH muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSA of the AbdH muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VRE colonisation
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in medical expenditure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Likelihood of job loss
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Nasal discharge scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean OQLQ overall score change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean pethidine injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to the first analgesic request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to deep vein thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ag85A-specific interferon gamma (IFNγ)+ CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: surgeon satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AMD progression rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to treatment (deltaCDAI > 100)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lifestyle changes undertaken
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevention of PPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Risk score for current WTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk score for ever WTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma M1 concentration (AUC0-24 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Detectability of glargine in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Level of uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of early rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity 6 months after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COP multiscale entropy (MSE) velocity sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COP medio-lateral standard deviation sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable disease ≥6 months or partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein oxidation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: neurocognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Corticosteroid side effects
Endpoint domain: Adverse events/effects
Primary endpoint: decreased risks of work injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: lost time injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: injury with three or more days of time loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Shortness of breath score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Women remaining undelivered during hospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Developmental communication disorder cluster frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine efficacy against severe RVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gained ≥1 lines of visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UDCVA of 20/25 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Within ±0.13 D spherical equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of telmisartan/rosuvastatin FDC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional status assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean lesion depth reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear attenuation coefficient increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obstacle avoidance success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance confidence scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postoperative pain score on VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Request for postoperative analgesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: medical costs during hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: cumulative net incremental costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Task performance speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Task performance errors
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Tes levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in liver function markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Reduction in signs of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Improvement in quality of life (QoL) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life improvement duration
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diagnosis of > or =CIN3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: complete protection from vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete protection from nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NYHA functional classes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CRQ gain
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PRQLQ scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in sputum neutrophil percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean absolute neutrophil count in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fewer mild exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score at 12-16 hr post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of supplemental analgesia use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of clients receiving test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-free status at 9.5 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased activity levels after discharge
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cohabitation odds
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Socio-economic position (SEP)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Participation in leisure and social activities
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: shorter recovery times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower heart rate recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: higher blood lactate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Interpersonal distress levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Strengthening of the alliance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in Y-BOCS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in surface area of breast induration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: day-28 adequate clinical and parasitological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom scores resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication of S pneumoniae carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: False-positive examinations
Endpoint domain: Adverse events/effects
Primary endpoint: grief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Disease Activity Score in 28 joints based on C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fat layer reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comfort during treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of hirsutism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores after skin test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort scores during pretreatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with treatment outcome
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Understanding of treatment options
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of treatment scheduling
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Physical functioning on day 3
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of CSPEB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative attitudes toward persons with serious mental illness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Support for gun restrictions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immunogenicity of CCIV compared to conventional vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of mild or moderate pain
Endpoint domain: Adverse events/effects
Primary endpoint: Time to restoration of the first sinus beat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease-free intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life assessed with the Urogenital Distress Inventory
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: carer anxiety and depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: carer quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Increase in folate intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in calcium intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Meeting parameters of the DASH diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Timed 'Up & Go' test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tinetti score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to rise unassisted after a fall
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in disability (Oswestry points)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough response to low-chloride solutions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: adherence to healthy eating and physical activity behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDS-UPDRS Motor Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bile acid synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bile acid and bilirubin detoxification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: conjugation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ability to cope with pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: venous volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: venous filling index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Patient preference between Xeomin and Botox
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BSDI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orbicularis strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Upper respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall well-being (global mood state)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mental/physical energy levels (vigor)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FJ consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMP9 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MMP9/TIMP2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MMP3 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MMP3/TIMP1 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: family adaptation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in left ventricular end systolic volume (LVESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fewer single premature ventricular contractions (PVCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fewer PVC runs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in PHQ-9 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SABA canister dispensings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in crestal bone level (CBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum concentration of CK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of low back pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in dentin hypersensitivity at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of errors on tests of executive functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: positive affect compared with baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: overall cognitive deterioration due to complications
Endpoint domain: Adverse events/effects
Primary endpoint: Decision in favor of EVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LARC use within four weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: LARC use three months after abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: immediate postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Plasma beta-endorphin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in distal coronary artery diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in coronary wedge pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: shorter hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: adverse sequelae from the administration of steroids
Endpoint domain: Adverse events/effects
Primary endpoint: CNS-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: 6-h predictive performance of pharmacokinetic model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: re-infarctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: apo A-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: stability of cemented and hybrid-fixation replacements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1, FVC, and FEV1%pred
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes